CD14 and B-cell chronic lymphocytic leukemia: Furthermore, 15 patients in the high CD14+HLA-DRlow/− expression group (n=24; >40% CD14+ monocytes) and three patients in the low expression group (n=25; <40% CD14+ monocytes) succumbed to CLL within four years, indicating that CD14+HLA-DRlow/− MDSCs may be a prognostic factor in CLL patients.